Concept

Sirtex

Summary
Sirtex Medical Limited is a medical device company, providing radioactive treatment for inoperable liver cancer called SIR-Spheres microspheres. Sirtex was established in 1997 in Australia and currently maintains offices and manufacturing facilities in the U.S., Australia, Germany and Singapore. Following an acquisition by China Grand Pharmaceutical and CDH Genetech, Sirtex de-listed from the Australian Securities Exchange (ASX:SRX) on Monday, September 24, 2018. The company is currently headed by Kevin R. Smith, who was appointed as CEO on October 16, 2019. How the SIR-Spheres microspheres work When SIR-Spheres microspheres are used to treat liver cancer, the treatment is called selective internal radiation therapy (called SIRT). This is a relatively new treatment option for people suffering inoperable liver cancer. SIR-Spheres are very small radioactive beads about one third the size of a human hair width that are injected into tumors within the liver. How they
About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.
Related publications

Loading

Related people

Loading

Related units

Loading

Related concepts

Loading

Related courses

Loading

Related lectures

Loading